Developing Unique Platform Technology
For Unmet Needs for Cancer Therapies and Beyond
SCROLL DOWN
Hwan Mook Kim
(CEO)
JONG HO LEE
(CFO)
Eun-Hee Ji
(CTO)
Chong Hwan Chang
(Vice-chairman/
Advisor)
Hyunseo Koo
(Patent Attorney/Director)
Keele Park
(Director)
Jong-Won Rhie
(MD. Ph.D.)
Jeong-Heum Baek
(MD. Ph.D.)
Elizabeth S. Song
(Ph.D.)
Sang-Bae Han
(Ph.D.)
Seung Hyun Oh
(Ph.D. D.V.M. DKCLAM)
Kwagng Won Jeong
(Ph.D.)
Hwan Mook Kim (CEO)
JONG HO LEE (CFO)
Eun-Hee Ji (CTO)
Chong Hwan Chang
(Vice-chairman/Advisor)
Hyunseo Koo
(Patent Attorney/Director)
Keele Park (Director)
Jong-Won Rhie (MD. Ph.D.)
Jeong-Heum Baek (MD. Ph.D.)
Elizabeth S. Song (Ph.D.)
Sang-Bae Han (Ph.D.)
Seung Hyun Oh
(Ph.D. D.V.M. DKCLAM)
Kwagng Won Jeong (Ph.D.)
Platform
“ Tumors cells and effector T cells share dependencies for glucose, glutamine, tryptophan, or arginine.
a
Tumor cells, by their extensive need of glucose, glutamine, tryptophan of arginine will impoverish the tumor area. This resource consumption from tumor cells will directly impact CD8 T cell metabolism leading to exhausted phenotype and indirectly, through metabolite secretion like for example lactate, stimulate the development of an immunosuppressive tumor micro-environment.b
At the opposite, if tumor cells have moderate metabolic demand, due to intrinsic characteristics or therapeutic manipulations, a fully functional anti-tumor immune response will mediated tumor elimination.”Ref: Modified from Cerezo and Rocchi, Nature (2020) 11:964
Strategy
Status of Clinical trials
2022-08-24
3
Phase 2 clinical trial of Metimedi Pharmaceutical Co., Ltd.'s anti-cancer
drug OMT-111(Pre-filled Syringe Formulation) was successfully processed as
planned, and the last patient is currently on investigation.
As soon as the last patient administration is completed, Phase 2 trial will be
completed and reported to the Ministry of Food and Drug Satety of Korea after
thorough clinical result analysis.
In addition, Metimedi is planning to write a journal paper about the clinical trials
and present to the global conference in the future. It will promote marketing
activities for global pharmmaceutical companies.
OMT-111 is further developed as an active tablet form named as Meti-101.
Meti-101 will improve the patient's convenience of taking medicines and is applicable
for various purposes.
On Apr. 21, 2022, clinical 1b/2a trials of Meti-101 was approved by the Ministry of
Food and Drug Safety of the Republic of Korea.
On Aug. 11, 2022, Meti-101 was conditionally approved for the first IRB at
Gachon University Gil Hospital. It is expected to receive final approval after
submitting the documents requested by Gil Hospital.
Once the final IRB is approved, the clinical trial contract will be singed and initiate
the trial on registered 30 patients.
Chronic Inflammatory Diseases(CID) Patent Registrati...
2022-08-24
2
Metimedi Pharmaceutical Co., Ltd.'s CID (Chronic Inflammatory Disease) patent
has been divided into three in the United States, and patent registration is under
investigation.
On Aug. 25, 2020, Metimedi's patents for multiple sclerosis, age-related macular
degeneration, and non-alconholic steatohepatitis (NASH) were passed the U.S.
Patent Office review and successfully registered in the U.S.
Moreover, on Jan. 26, 2021, Metimedi gained the approval of its patent for
Alzheimer's disease, Parkinson's disease, atherosclerosis, and inflammatory bowl
dlsease in the U.S. Patent Office.
Metimedi is planning to get more patents on other chronic inflammatory diseases.
Formulation Patent Registration Status
2022-08-24
2
On July. 7, 2022, the formulation patent for the anti-cancer drug of Metimedi
Pharmaceutical Co., Ltd. was successfully registered in Mexico after passing the
the patent registration by the Mexico Patent Office.
As a result, Metimedi's anti-cancer drug formulation patent has been registered
in two countries, the United States (registered March, 29, 2022) and Mexico.
Currently,Metimedi is on the process of expanding its formulation patent further
in 13 countries including European Patent Convention, Taiwan, and Japan.
말기 대장암 치료제 METI-101 임상결과 언론 보도 기사
2024-04-26
0
Anti-EGFR Targeting 말기 대장암 치료제 METI-101 임상결과
부작용이 거의 없는 뛰어난 안전성과 기존 치료요법인 cetuximab recellenge 요법의
전체생존기간 중앙값(8~9개월) 보다 약 15개월 이상 수명연장이 기대되는
전체생존기간 중앙값(23.4개월))의 뛰어난 효능이 확인되었습니다.
자세한 내용은 별첨 약업신문 기사를 참고하세요
정기주주총회 소집공고(Announcement of the convening ...
2024-03-19
0
정기주주총회 소집공고(Announcement of the convening ...
2023-03-08
0
Contact us
경기 의왕시 이미로 40 (인덕원IT밸리) D동 701
Eun-Hee Ji, Ph.D.
Chief Technology Officer
Phone +82-32-205-0541
Email ehji@metimedi.com
Heeyeol Yeom
Manager, Business Development
Phone +82-32-205-0541
Email heeyeol42@metimedi.com
